Targeting Leukemia-Initiating Cells in Acute Lymphoblastic Leukemia

Area of Science:

• Hematology
• Cancer Stem Cell Biology
• Leukemia Research

Background:

• Leukemia-initiating cells (LICs) are increasingly recognized as the stem-like cells responsible for generating and sustaining leukemias.
• These cells possess self-renewal capabilities and differentiate into non-LIC tumor cells, analogous to normal hematopoietic stem cells.
• LICs are functionally distinct from bulk leukemia cells and are regulated by specific molecular and epigenetic mechanisms.

Purpose of the Study:

• To review biological and clinical aspects of LICs in acute lymphoblastic leukemia (ALL).
• To explore therapeutic strategies targeting LICs for improved ALL treatment outcomes.
• To highlight novel mechanisms of LIC propagation and immunotherapy approaches.

Main Methods:

• Review of immunophenotypic characterization of LIC-enriched subsets in human and mouse ALL models.
• Analysis of emerging therapeutics targeting signaling pathways crucial for LIC progression and maintenance.
• Examination of epigenetic and age-related mechanisms influencing LIC propagation.
• Assessment of immunotherapy strategies for eradicating LICs in relapsed/refractory ALL.

Main Results:

• LICs are critical drivers of ALL, exhibiting distinct properties from bulk leukemia cells.
• Conventional treatments are often ineffective against LICs, contributing to disease relapse.
• Specific signaling pathways, epigenetic factors, and age-related mechanisms influence LIC behavior.
• Immunotherapy approaches are being developed to target LIC-enriched subsets.

Conclusions:

• LICs represent a key therapeutic target for achieving a definitive cure for ALL.
• Novel treatments specifically designed to eliminate LICs are essential for overcoming treatment resistance.
• Targeting LICs holds significant promise for improving outcomes in relapsed and refractory ALL cases.